Denmark's Stenocare Q3 sales rise on Danish market growth
Denmark's Stenocare Q3 sales rise on Danish market growth
Overview
Denmark medical cannabis supplier's Q3 sales rose 53% yr/yr, driven by Danish market growth
Company posted negative EBITDA in Q3 after five positive quarters, citing market and regulatory factors
Company maintains outlook for positive full-year EBITDA despite Q3 loss
Outlook
Stenocare maintains expectation of positive EBITDA for full-year 2026
Company says German market outlook affected by prescription and reimbursement changes
Company warns of potential supply gap for Bedrocan products in Denmark from 2027
Result Drivers
DANISH MARKET - Co said Q3 sales growth was driven by continued momentum in Denmark across oil and dried flower products
GERMAN REGULATORY CHANGES - Co said sales in Germany were below expectations due to changes in prescription and reimbursement rules
SUPPLY UNCERTAINTY - Co said future supply of Bedrocan products faces uncertainty due to changes in Dutch export policy
Company press release: ID:nWkr2qCh1N
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales |
| DKK 2.94 mln |
|
Q3 Loss Per Share |
| DKK 0.02 |
|
Q3 EBITDA |
| -DKK 244,000 |
|
Reuters Recommended Reads
Oct 28 - Denmark's Alm. Brand Q3 insurance revenue rises on Personal Lines unit strength
Oct 28 - Denmark's Norden Q3 net profit more than doubles on strong markets; raises FY guidance
Oct 28 - Denmark's Broedrene A & O Johansen Q3 revenue rises 22.9%, lifts 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)